Xenetic Biosciences, Inc.
XBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | 74.1% | -0.6% | -8.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $1 | $1 | $1 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $1 | $1 | $1 | $1 |
| G&A Expenses | $1 | $1 | $1 | $1 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $1 | $2 | $2 |
| Operating Income | -$1 | -$1 | -$1 | -$1 |
| % Margin | -53% | -122.8% | -158.9% | -169.4% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$1 | -$1 | -$1 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$1 | -$1 | -$1 |
| % Margin | -49.7% | -116.7% | -152.2% | -162.5% |
| EPS | -0.33 | -0.45 | -0.59 | -0.68 |
| % Growth | 26.7% | 23.7% | 13.2% | – |
| EPS Diluted | -0.33 | -0.45 | -0.59 | -0.68 |
| Weighted Avg Shares Out | 2 | 2 | 2 | 2 |
| Weighted Avg Shares Out Dil | 2 | 2 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | -$0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$1 | -$1 | -$1 |
| % Margin | -50.9% | -122.8% | -158.9% | -169.4% |